Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jun;14(6):1748-1752.
doi: 10.21037/jtd-22-269.

Critical points in the management of EGFR-mutated non-small cell lung cancer

Francesca Casaluce  1 , Cesare Gridelli  1
Affiliations
Editorial

Critical points in the management of EGFR-mutated non-small cell lung cancer

Francesca Casaluce et al. J Thorac Dis. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-269/coif). CG in the past two years has received the funding listed below from the following sources as an advisory board member, Speaker bureau member or consultant: Amgen, Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, Karyopharm, Menarini, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda. The other author has no conflicts of interest to declare.

Comment on

References

    1. Wang G, Lin Y, Zheng L, et al. A new method for accurately localizing and resecting pulmonary nodules. J Thorac Dis 2020;12:4973-84. 10.21037/jtd-20-2089 - DOI - PMC - PubMed
    1. Du W, Zhao Y, Xuan Y, et al. Different efficacy in the non-small cell lung cancer patient with bilateral synchronous lesions treated with neoadjuvant gefitinib therapy: a case report. J Thorac Dis 2020;12:1582-7. 10.21037/jtd.2020.02.60 - DOI - PMC - PubMed
    1. Sun L, Guo YJ, Song J, et al. Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials. Front Oncol 2020;10:586596. 10.3389/fonc.2020.586596 - DOI - PMC - PubMed
    1. Hosomi Y, Morita S, Sugawara S, et al. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol 2020;38:115-23. 10.1200/JCO.19.01488 - DOI - PubMed
    1. Noronha V, Patil VM, Joshi A, et al. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol 2020;38:124-36. 10.1200/JCO.19.01154 - DOI - PubMed